Soft tissue sarcoma is a cancer that starts in muscles, fat, blood vessels, nerves, or other connective tissues. About 13,000 people are diagnosed with it in the US each year. Treatment typically involves surgery, often combined with radiation, and chemotherapy for high-risk or metastatic disease.
What's actually going on in research
Trials are testing checkpoint inhibitors alone and combined with other drugs, targeted therapies for specific sarcoma subtypes, and antibody-drug conjugates that deliver chemotherapy directly to tumor cells. Researchers are also studying liposomal doxorubicin formulations, trabectedin combinations, and ways to predict which sarcomas will respond to immunotherapy.
Subtype-specific treatments
Different sarcomas have different molecular drivers, and trials now test drugs matched to subtype. For example, some studies target MDM2 amplification in liposarcoma or specific fusion proteins in synovial sarcoma.
Immunotherapy combinations
Checkpoint inhibitors work in only some sarcoma patients, so trials are pairing them with vaccines, radiation, or drugs that make tumors more visible to the immune system. The goal is to expand the number of people who benefit.
Antibody-drug conjugates
These drugs attach chemotherapy to an antibody that seeks out sarcoma cells. Early studies suggest they may work in sarcomas that express certain surface proteins, with fewer side effects than standard chemotherapy.
What to know before you search
Eligibility often depends on sarcoma subtype, disease stage, prior treatments, and whether the tumor can be surgically removed.
What types of trials are currently open
- Targeted therapy trials — Testing drugs that block specific mutations or proteins found in certain sarcoma subtypes, aiming for more precise treatment with fewer side effects.
- Immunotherapy trials — Testing checkpoint inhibitors, cancer vaccines, or combinations that help the immune system recognize and attack sarcoma cells.
- Chemotherapy trials — Studying new chemotherapy drugs or combinations, often comparing them to standard doxorubicin-based regimens.
- Surgery trials — Comparing different surgical approaches or timing of surgery relative to radiation and chemotherapy.
- Biomarker studies — Collecting tumor samples to identify genetic features that predict treatment response or prognosis.
Recently added Soft Tissue Sarcoma trials
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
The primary objective of this trial is to evaluate the safety and tolerability of the tumor neoantigen vaccine (SarcVac) in combination with a PD-1 antibody, with or without tumor-specific lymphocytes, in patients with advanced bone and soft tissue sarcoma who have failed first-line treatment. The secondary objectives are to assess the preliminary efficacy of SarcVac combined with a PD-1 antibody, with or without tumor-specific lymphocytes, in these patients and to evaluate whether the vaccine's efficacy demonstrates dose dependency.
Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients
The objective of this prospective study is to capture the quality of life of patients with locally advanced or metastatic sarcoma, and investigate the effectiveness of support provided through a personalized web-based platform.
Find Soft Tissue Sarcoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.